280 results
8-K
EX-99.1
BIIB
Biogen Inc
24 Apr 24
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
7:02am
litigation, as all are hard to predict, or any impact of potential tax or healthcare reform. Biogen may incur charges, realize gains or losses, or experience … of pending or future significant litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material
8-K
EX-99.1
7sza4371tpan9robwa
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
8-K
EX-3.2
aaeg2 nhklmjn
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-3.1
kcran2yb3s2jhr
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-99.1
q2i867fikh xc82xm4o
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K
1gx4v56 jehy
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-10.1
apk6p96 9d
1 Sep 23
Entry into a Material Definitive Agreement
4:36pm
DEFA14A
8aerwxl6utcmtdxj4hym
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
EX-2.1
ur4oy
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-3.1
mw7gl w2a
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
m11rfhx5q
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
e21no32cz7
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.2
q1uisxh1083i2ls4g
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.3
co2f 3p6m9w
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
DEFA14A
k28o1k5z69173p111
28 Jul 23
Additional proxy soliciting materials
7:13am